Meeting
2021 Genitourinary Cancers Symposium
Anaplastic features (AnaF) and DNA-damage repair pathway (DDR) mutations in metastatic castration-resistant prostate cancer (mCRPC).
Authors
Vincent Chau
National Institutes of Health, Bethesda, MD
Vincent Chau , Ravi Amrit Madan , Marijo Bilusic , Lisa M. Cordes , Jennifer L. Marte , Helen Owens , Amy Hankin , James L. Gulley , Jung-Min Lee , William L. Dahut , Fatima Karzai
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT02484404
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 92)
DOI
10.1200/JCO.2021.39.6_suppl.92
Abstract #
92
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Alliance A031902 (CASPAR): A randomized phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2022 ASCO Annual Meeting
Alliance A031902 (CASPAR): A randomized, phase (ph) 3 trial of enzalutamide with rucaparib/placebo in first-line metastatic castration-resistant prostate cancer (mCRPC).
First Author: Arpit Rao
Poster
2017 ASCO Annual Meeting
Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
First Author: Fatima Karzai
Poster
2024 ASCO Genitourinary Cancers Symposium
The efficacy and safety of tinengotinib in patients with heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
First Author: Guo Hongqian